← Back to Clinical Trials
Recruiting NCT05977218

NCT05977218 DIgitAl diabeTES Treatment - the Healthy Eating, heaLthy Patients Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05977218
Status Recruiting
Phase
Sponsor Linkoeping University
Condition Type 2 Diabetes
Study Type INTERVENTIONAL
Enrollment 900 participants
Start Date 2025-08-25
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
FoodSwitch

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 900 participants in total. It began in 2025-08-25 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled trial will assess the impact of the FoodSwitch mobile app, which provides interpretive front-of-pack labelling via barcode scanning, in 900 Swedish adults with type 2 diabetes. Participants will be randomized to app + standard advice or standard advice alone. The primary outcome is change in HbA1c at 6 months; secondary outcomes include anthropometrics, quality of life, medication use, hospitalizations, and mortality.

Eligibility Criteria

Inclusion criteria: * Age between 18 and 75 years * Self-reported type 2 diabetes with a duration of ≥2 years * Regularly grocery shopping Exclusion criteria: * No access to BankID (a digital identification system commonly used in Sweden) * Failure to complete eligibility screening and run-in periods

Contact & Investigator

Central Contact

Lana Hebib, MD

✉ lana.hebib@liu.se

📞 013-28 10 00

Principal Investigator

Karin Rådholm, MD, PhD

STUDY DIRECTOR

Linkoeping University

Frequently Asked Questions

Who can join the NCT05977218 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05977218 currently recruiting?

Yes, NCT05977218 is actively recruiting participants. Contact the research team at lana.hebib@liu.se for enrollment information.

Where is the NCT05977218 trial being conducted?

This trial is being conducted at Linköping, Sweden.

Who is sponsoring the NCT05977218 clinical trial?

NCT05977218 is sponsored by Linkoeping University. The principal investigator is Karin Rådholm, MD, PhD at Linkoeping University. The trial plans to enroll 900 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology